A booster dose of the Pfizer-BioNTech COVID-19 vaccine appears to offer strong protection against the Omicron variant, the companies said on Wednesday.
They said a third dose of their vaccine delivers similar levels of neutralizing antibodies to Omicron, comparable to two doses against the original coronavirus and other variants that have emerged.
Blood samples from those who received only the primary series of vaccine showed, on average, a 25-fold decrease in antibodies to the new variant, suggesting that two doses of the vaccine may not be enough to protect against infection with Omicron.
The companies said the results are preliminary. The results have been detailed in a press release and the full data has not yet been made available to other scientists for review.
Read the full story here on NBCNews.com.